Table 5.

ORs (95% CIs) of invasive breast cancer for a doubling in estrone metabolite or metabolite ratio by ER status, postmenopausal women, the NYUWHS and the NSMSC

ER status
ER+ER−
Estrone metaboliteOR (95% CIs)POR (95% CIs)PP for heterogeneity
Cases/controls254/25470/70
2-OHE1, pg/mL
 Unadjusteda0.91 (0.68–1.22)0.521.82 (0.80–4.18)0.160.12
 Adjusted for estroneb0.72 (0.52–1.00)0.052.19 (0.90–5.33)0.080.02
 Multivariate-adjustedc0.67 (0.48–0.94)0.022.83 (0.83–9.70)0.100.03
16α-OHE1, pg/mL
 Unadjusteda0.95 (0.65–1.38)0.771.32 (0.60–2.93)0.490.45
 Adjusted for estroneb0.89 (0.60–1.32)0.561.46 (0.63–3.39)0.370.29
 Multivariate-adjustedc0.86 (0.57–1.29)0.461.60 (0.59–4.36)0.350.26
2-OHE1:16α-OHE1 ratio
 Unadjusteda0.95 (0.74–1.23)0.721.22 (0.66–2.24)0.530.47
 Adjusted for estroneb0.84 (0.64–1.10)0.201.23 (0.67–2.27)0.500.26
 Multivariate-adjustedc0.81 (0.61–1.07)0.141.17 (0.53–2.56)0.700.39
  • aConditional logistic regression (matching variables: age, date of blood donation, cohort).

  • bConditional logistic regression adjusting for log-transformed estrone levels.

  • cConditional logistic regression adjusting for log-transformed estrone levels, log-transformed BMI, height (continuous), age at menarche (continuous), age at menopause (continuous), family history of breast cancer (negative, positive), age at first birth/parity (≤ 20, 21–25, 26–30, >30 years, or nulliparous), oral contraceptive use (never, ever), HRT use (never, ever), and complete oophorectomy (no, yes).